(Adnkronos) – Passamonti (Director of Hematology Varese): “They are myeloid neoplasms, such as polycythemia, thrombocythemia and myelofibrosis, united by some mutations such as those of JAK2, CALR or MPL, and vascular risks such as thrombosis and hemorrhages.”
Welcome! Log into your account
Recover your password
A password will be e-mailed to you.